C91.12
Chronic lymphocytic leukemia of B-cell type in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Chronic lymphocytic leukemia (CLL) of B-cell type is a gradual, ongoing form of blood cancer that affects the lymphocytes, a type of white blood cell involved in immune response. When this disease returns after treatment, it’s referred to as a relapse. The ICD-10 code C91.12 specifically identifies cases where CLL has reoccurred after initial therapy. Recognizing the nature of this condition helps in understanding the disease course, potential symptoms, and treatment options.
Causes & Symptoms
Clinical Causes: The precise cause of CLL relapse isn’t fully understood, but certain factors may influence its recurrence, including: - Genetic mutations within the cancer cells - Resistance to initial treatments - The natural progression of the disease - Immune system factors - Environmental exposures and lifestyle factors may also play a role, but more research is needed to establish clear links.
Key Symptoms: Since CLL often develops gradually, some individuals may experience minimal or no symptoms initially. When symptoms do occur, they might include: - Swollen lymph nodes, especially on the neck, armpits, or groin - Fatigue and weakness - Fever and night sweats - Unexplained weight loss - Frequent infections or infections that are hard to control - Easy bruising or bleeding due to blood platelet problems - Abdominal discomfort caused by enlarged spleen or liver In relapse, these symptoms could intensify or reappear after period of remission, signaling the disease's return.
Diagnostic & Treatment
Diagnosis Path: Diagnosing a relapse of CLL involves a combination of tests and assessments: - Blood tests: Complete blood count (CBC) to observe abnormal lymphocyte levels - Bone marrow biopsy: To evaluate marrow involvement - Imaging studies: Such as CT scans to identify lymph node or organ enlargement - Immunophenotyping: To confirm B-cell lineage of the leukemia - Molecular and genetic testing: To identify specific mutations that may influence treatment options Monitoring patients over time with regular check-ups is crucial for detecting early signs of relapse.
Treatment Protocols: Treatment strategies for relapsed CLL are tailored based on various factors, including the patient’s overall health, previous treatments, and disease progression: - Targeted therapies: Such as BTK inhibitors (e.g., ibrutinib) or BCL-2 inhibitors (e.g., venetoclax) - Chemotherapy: Using agents selected for their effectiveness in re-inducing remission - Monoclonal antibodies: Like rituximab, which target specific proteins on leukemia cells - Combination therapies: To improve outcomes and prolong remission - Supportive care: Including treatments for symptoms, managing infections, and addressing side effects New treatments and clinical trials may offer additional options for those experiencing relapse, emphasizing the importance of specialized medical guidance.
Clinical Advice & FAQs
Billing Guidance
Is C91.12 a billable ICD-10 code?
Yes, C91.12 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.12?
Clinical documentation must specify the nature of Chronic lymphocytic leukemia of B-cell type in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference